Consensus Needs to Come Down on Intercept (ICPT) after FDA Review is Extended - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
FDA Pushed Back Intercept Pharma's (ICPT) PDUFA Date; Seeks More Data - Baird Maintains Outperform
December 18, 2015 7:41 AM ESTBaird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the FDA pushed out its Prescription Drug User Fee Act (PDUFA) date for the priority review of obeticholic acid (OCA) in primary biliary cholangitis (PBC). The... More
Intercept Pharma (ICPT) Announces PDUFA Date Extension for OCA in PBC
December 17, 2015 5:01 PM ESTIntercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of obeticholic acid (OCA) in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC).... More
